{"DataElement":{"publicId":"6820478","version":"1","preferredName":"Disease or Disorder Best Hematologic Response Outcome of Therapy Plasma Cell Myeloma Status Type","preferredDefinition":"A description of the best hematologic response to therapy for plasma cell myeloma.","longName":"6820474v1.0:2950502v1.1","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"6820474","version":"1","preferredName":"Disease or Disorder Best Hematologic Response Outcome of Therapy","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Having the most positive qualities._An evaluation of the hematologic response of the disease to the therapy._The result of therapy for a given disease or condition in a patient or group of patients.","longName":"6820505v1.0:4243575v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"6820505","version":"1","preferredName":"Disease or Disorder Best Hematologic Response","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Having the most positive qualities.:An evaluation of the hematologic response of the disease to the therapy.","longName":"C2991:C25432:C123622","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Best","conceptCode":"C25432","definition":"Having the most positive qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hematologic Response","conceptCode":"C123622","definition":"An evaluation of the hematologic response of the disease to the therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E49CCAA-23FE-0E89-E053-F662850A6A18","latestVersionIndicator":"Yes","beginDate":"2019-07-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-22","modifiedBy":"ONEDATA","dateModified":"2019-07-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4243575","version":"1","preferredName":"Outcome of Therapy","preferredDefinition":"The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C18919","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Outcome of Therapy","conceptCode":"C18919","definition":"The result of therapy for a given disease or condition in a patient or group of patients.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F522D8B8-82F1-A069-E040-BB89AD435FEC","latestVersionIndicator":"Yes","beginDate":"2014-03-21","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-03-21","modifiedBy":"ONEDATA","dateModified":"2014-03-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E468AC5-552E-699D-E053-F662850A1EF1","latestVersionIndicator":"Yes","beginDate":"2019-07-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-22","modifiedBy":"KUMMEROA","dateModified":"2020-02-03","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2950502","version":"1.1","preferredName":"Plasma Cell Myeloma Status Type","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)._A condition or state at a particular time._Type; a subdivision of a particular kind of thing.","longName":"2950502v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Near complete remission (nCR)","valueDescription":"Near complete remission","ValueMeaning":{"publicId":"3966881","version":"1","preferredName":"Near complete remission","longName":"3966881","preferredDefinition":"A subgroup of complete response of multiple myeloma or plasma cell leukemia.  It is characterized by less than 5% plasma cells in the bone marrow, unmeasurable serum and urine monoclonal proteins by electrophoresis, and positive serum and/or urine immunofixation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Near Complete Response of Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C123275","definition":"A subgroup of complete response of multiple myeloma or plasma cell leukemia.  It is characterized by less than 5% plasma cells in the bone marrow, unmeasurable serum and urine monoclonal proteins by electrophoresis, and positive serum and/or urine immunofixation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EC1C6D05-D75F-12B7-E040-BB89AD4304E6","latestVersionIndicator":"Yes","beginDate":"2013-11-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Changed definition per request from A.Kummerow. mc 8/5/15 Added new concept annotation. mc 8/12/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC1C6D05-D777-12B7-E040-BB89AD4304E6","beginDate":"2013-02-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-26","modifiedBy":"ONEDATA","dateModified":"2013-11-26","deletedIndicator":"No"},{"value":"Complete remission (CR)","valueDescription":"Complete Response of Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"3541528","version":"1","preferredName":"Complete Response of Multiple Myeloma or Plasma Cell Leukemia","longName":"3541528","preferredDefinition":"Complete response of multiple myeloma or plasma cell leukemia is characterized by negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and less than 5% plasma cells in the bone marrow (confirmation with repeat bone marrow biopsy not needed). Complete response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy complete response requirements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Response of Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C70639","definition":"Complete response of multiple myeloma or plasma cell leukemia is characterized by negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and less than 5% plasma cells in the bone marrow (confirmation with repeat bone marrow biopsy not needed). Complete response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy complete response requirements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C661F4F8-E093-BB1A-E040-BB89AD436C64","latestVersionIndicator":"Yes","beginDate":"2012-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-08-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E97E4098-B2C8-CA79-E040-BB89AD4371C0","beginDate":"2009-10-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"3241403","version":"1","preferredName":"Unknown","longName":"3241403","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4499CFB-7A3A-DD4D-E040-BB89AD4307BF","latestVersionIndicator":"Yes","beginDate":"2011-05-27","endDate":null,"createdBy":"DWARZEL","dateCreated":"2011-05-27","modifiedBy":"MMADDINENI","dateModified":"2023-12-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E97DE8A8-6402-1ABC-E040-BB89AD4346F4","beginDate":"2011-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","deletedIndicator":"No"},{"value":"Partial remission (PR)","valueDescription":"Partial Response of Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"2691337","version":"1","preferredName":"Partial Response of Multiple Myeloma or Plasma Cell Leukemia","longName":"2691337","preferredDefinition":"Partial response of multiple myeloma or plasma cell leukemia is characterized by a 50% or greater reduction in serum M-protein, and reduction in 24-hour urinary M-protein by 90% or more or to less than 200 mg/24 hours. If the serum and urine M-protein are unmeasurable (i.e., do not meet any of the following criteria: 1. serum M-protein at least 1 g/dL; 2. urine M-protein at least 200 mg/24 hours; a 50% or more decrease in the difference between involved and uninvolved free light chain levels is required in place of the M-protein criteria (provided the serum free light chain assay shows involved level at least 10 mg/dL and the serum free light chain is abnormal). If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, a 50% or more reduction in plasma cells is required in place of M-protein, provided the baseline bone marrow plasma cell percentage was 30% or more. In addition to the above listed criteria, a 50% or more reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. Partial response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy partial response requirements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Response of Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C70641","definition":"Partial response of multiple myeloma or plasma cell leukemia is characterized by a 50% or greater reduction in serum M-protein, and reduction in 24-hour urinary M-protein by 90% or more or to less than 200 mg/24 hours. If the serum and urine M-protein are unmeasurable (i.e., do not meet any of the following criteria: 1. serum M-protein at least 1 g/dL; 2. urine M-protein at least 200 mg/24 hours; a 50% or more decrease in the difference between involved and uninvolved free light chain levels is required in place of the M-protein criteria (provided the serum free light chain assay shows involved level at least 10 mg/dL and the serum free light chain is abnormal). If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, a 50% or more reduction in plasma cells is required in place of M-protein, provided the baseline bone marrow plasma cell percentage was 30% or more. In addition to the above listed criteria, a 50% or more reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. Partial response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy partial response requirements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D3B8450-4320-6519-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-24","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Removed and then added the concept due to definition change in NCIt. mc 11/11/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E97E4098-B300-CA79-E040-BB89AD4371C0","beginDate":"2009-10-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","deletedIndicator":"No"},{"value":"Progressive disease (PD)","valueDescription":"Progression of Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"2691336","version":"1","preferredName":"Progression of Multiple Myeloma or Plasma Cell Leukemia","longName":"2691336","preferredDefinition":"Progression of multiple myeloma or plasma cell leukemia requires any one or more of the following: Increase of 25% or more from baseline in: serum M-component with an absolute increase 0.5 g/dL or more (for progressive disease, serum M-component increases of 1 g/dL or more are sufficient to define relapse if the starting M component is 5 g/dL or more); urine M-component with an absolute increase 200 mg. or more/ 24 hours; for recipients without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase more than 10 mg/dL); bone marrow plasma cell percentage (absolute percentage 10% or more); definite development of new bone lesions or soft tissue plasmacytomas, or definite increase in the size of any existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium more than 11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder. Progression of disease requires two consecutive assessments made at any time before classification as disease progression, and/or the institution of any new therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progression of Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C70643","definition":"Progression of multiple myeloma or plasma cell leukemia requires any one or more of the following: Increase of 25% or more from baseline in: serum M-component with an absolute increase 0.5 g/dL or more (for progressive disease, serum M-component increases of 1 g/dL or more are sufficient to define relapse if the starting M component is 5 g/dL or more); urine M-component with an absolute increase 200 mg. or more/ 24 hours; for recipients without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase more than 10 mg/dL); bone marrow plasma cell percentage (absolute percentage 10% or more); definite development of new bone lesions or soft tissue plasmacytomas, or definite increase in the size of any existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium more than 11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder. Progression of disease requires two consecutive assessments made at any time before classification as disease progression, and/or the institution of any new therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D3B8450-42F9-6519-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-24","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Removed and added back concept to update definition to latest NCIt. mc 11/11/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E97E4098-B316-CA79-E040-BB89AD4371C0","beginDate":"2009-10-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","deletedIndicator":"No"},{"value":"Relapse from CR (Rel) (untreated)","valueDescription":"Relapse from Complete Response of Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"2691335","version":"1","preferredName":"Relapse from Complete Response of Multiple Myeloma or Plasma Cell Leukemia","longName":"2691335","preferredDefinition":"Relapse from complete response of multiple myeloma or plasma cell leukemia requires one or more of the following: reappearance of serum or urine M-protein by immunofixation or electrophoresis; development of 5% or more plasma cells in the bone marrow (relapse from complete response has a 5% cutoff vs.10% for other categories of relapse); appearance of any other sign of progression (e.g., new plasmacytoma, lytic bone lesion, hypercalcemia). Relapse requires two consecutive assessments made at any time before classification as relapse, and/or the institution of any new therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Relapse from Complete Response of Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C70645","definition":"Relapse from complete response of multiple myeloma or plasma cell leukemia requires one or more of the following: reappearance of serum or urine M-protein by immunofixation or electrophoresis; development of 5% or more plasma cells in the bone marrow (relapse from complete response has a 5% cutoff vs.10% for other categories of relapse); appearance of any other sign of progression (e.g., new plasmacytoma, lytic bone lesion, hypercalcemia). Relapse requires two consecutive assessments made at any time before classification as relapse, and/or the institution of any new therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D3B8450-42D2-6519-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-24","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E97E4098-B32C-CA79-E040-BB89AD4371C0","beginDate":"2009-10-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","deletedIndicator":"No"},{"value":"Stable disease (SD)","valueDescription":"Stable Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"2691333","version":"1","preferredName":"Stable Multiple Myeloma or Plasma Cell Leukemia","longName":"2691333","preferredDefinition":"Stable multiple myeloma or plasma cell leukemia is characterized by not meeting the criteria for complete response, very good partial response, partial response or progression of disease. Stable disease requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy stable disease requirements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C70642","definition":"Stable multiple myeloma or plasma cell leukemia is characterized by not meeting the criteria for complete response, very good partial response, partial response or progression of disease. Stable disease requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy stable disease requirements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D3B8450-4284-6519-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-24","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E97E4098-B342-CA79-E040-BB89AD4371C0","beginDate":"2009-10-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","deletedIndicator":"No"},{"value":"Stringent complete remission (sCR)","valueDescription":"Stringent Complete Response (sCR) of Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"2982983","version":"1","preferredName":"Stringent Complete Response (sCR) of Multiple Myeloma or Plasma Cell Leukemia","longName":"2982983","preferredDefinition":"Stringent complete response (sCR) of multiple myeloma or plasma cell leukemia is characterized by complete response plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence (confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the kappa/lambda ratio. An abnormal kappa/lambda ratio by immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting the presence of an abnormal clone is kappa/lambda of > 4:1 or < 1:2.).  Stringent complete response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy stringent complete response requirements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stringent Complete Response (sCR) of Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C70637","definition":"Stringent complete response (sCR) of multiple myeloma or plasma cell leukemia is characterized by complete response plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence (confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the kappa/lambda ratio. An abnormal kappa/lambda ratio by immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting the presence of an abnormal clone is kappa/lambda of > 4:1 or < 1:2.).  Stringent complete response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy stringent complete response requirements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C991ADD-0123-711A-E040-BB89AD432C85","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E97E4098-B358-CA79-E040-BB89AD4371C0","beginDate":"2009-10-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","deletedIndicator":"No"},{"value":"Not applicable","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"2838911","version":"1","preferredName":"Not Applicable","longName":"2838911","preferredDefinition":"Determination that a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62AB59ED-A641-4EBE-E040-BB89AD4348C8","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"CLOHNES","dateModified":"2022-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E97DE8A8-6448-1ABC-E040-BB89AD4346F4","beginDate":"2013-02-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","deletedIndicator":"No"},{"value":"Very good partial remission (VGPR)","valueDescription":"Very Good Partial Response of Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"3541530","version":"1","preferredName":"Very Good Partial Response of Multiple Myeloma or Plasma Cell Leukemia","longName":"3541530","preferredDefinition":"Very good partial response of multiple myeloma or plasma cell leukemia is characterized by serum and urine M-protein detectable by immunofixation but not on electrophoresis, or at least 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours.  Very good partial response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy very good partial response requirements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Very Good Partial Response of Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C70638","definition":"Very good partial response of multiple myeloma or plasma cell leukemia is characterized by serum and urine M-protein detectable by immunofixation but not on electrophoresis, or at least 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours. Very good partial response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy very good partial response requirements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C661F4F8-E11E-BB1A-E040-BB89AD436C64","latestVersionIndicator":"Yes","beginDate":"2012-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-08-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E97E4098-B36E-CA79-E040-BB89AD4371C0","beginDate":"2009-10-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","deletedIndicator":"No"},{"value":"Relapse","valueDescription":"Clinical Relapse of Multiple Myeloma or Plasma Cell Leukemia by IMWG","ValueMeaning":{"publicId":"5025911","version":"1","preferredName":"Clinical Relapse of Multiple Myeloma or Plasma Cell Leukemia by IMWG","longName":"5025911","preferredDefinition":"Relapse of multiple myeloma or plasma cell leukemia is defined as follows: Development of new soft tissue plasmacytomas or bone lesions; Definite increase in the size of existing plasmacytomas or bone lesions. A definite increase is defined as a 50% (and at least 1 cm) increase as measured serially by the sum of the products of the cross-diameters of the measurable lesion; Hypercalcemia (> 11.5 mg/dL) [2.65 mmol/L]; Decrease in hemoglobin of > 2 g/dL [1.25 mmol/L]; and rise in serum creatinine by 2 mg/dL or more [177 mmol/L or more]. (International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma. <http://myeloma.org/ArticlePage.action?articleId=2994>)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Relapse of Multiple Myeloma or Plasma Cell Leukemia by IMWG","conceptCode":"C123908","definition":"Relapse of multiple myeloma or plasma cell leukemia is defined as follows: Development of new soft tissue plasmacytomas or bone lesions; Definite increase in the size of existing plasmacytomas or bone lesions. A definite increase is defined as a 50% (and at least 1 cm) increase as measured serially by the sum of the products of the cross-diameters of the measurable lesion; Hypercalcemia (> 11.5 mg/dL) [2.65 mmol/L]; Decrease in hemoglobin of > 2 g/dL [1.25 mmol/L]; and rise in serum creatinine by 2 mg/dL or more [177 mmol/L or more]. (International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma. <http://myeloma.org/ArticlePage.action?articleId=2994>)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"20D0CFDD-3621-CEBD-E050-BB89AD4303AB","latestVersionIndicator":"Yes","beginDate":"2015-09-28","endDate":null,"createdBy":"ZHANGW","dateCreated":"2015-09-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Added concept per request by NMDP/A.Kummerow. 11/12/15 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"20D0CFDD-363A-CEBD-E050-BB89AD4303AB","beginDate":"2015-09-28","endDate":null,"createdBy":"ZHANGW","dateCreated":"2015-09-28","modifiedBy":"ONEDATA","dateModified":"2015-09-28","deletedIndicator":"No"},{"value":"No response (NR) / stable disease (SD)","valueDescription":"No response / stable disease","ValueMeaning":{"publicId":"6796615","version":"1","preferredName":"No response / stable disease","longName":"6796615","preferredDefinition":"Not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD requirements","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C4E1C27-350C-7D9F-E053-F662850A0654","latestVersionIndicator":"Yes","beginDate":"2019-06-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-27","modifiedBy":"KUMMEROA","dateModified":"2019-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C4E1C27-3524-7D9F-E053-F662850A0654","beginDate":"2019-06-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-27","modifiedBy":"ONEDATA","dateModified":"2019-06-27","deletedIndicator":"No"},{"value":"Continued complete response (CCR)","valueDescription":"Continued complete response","ValueMeaning":{"publicId":"6769541","version":"1","preferredName":"Continued complete response","longName":"6769541","preferredDefinition":"For recipients already in CR prior to the start of the preparative regimen","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"89A36892-10D6-64AD-E053-F662850A9C1A","latestVersionIndicator":"Yes","beginDate":"2019-05-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-05-24","modifiedBy":"ONEDATA","dateModified":"2019-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F25F63A-CEB3-2AC3-E053-F662850A61D6","beginDate":"2019-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-08-02","modifiedBy":"ONEDATA","dateModified":"2019-08-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3308042","version":"1","preferredName":"Plasma Cell Myeloma Status Type","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001):A condition or state at a particular time.:Type; a subdivision of a particular kind of thing.","longName":"C3242:C25688:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B20386B0-DB92-9FF5-E040-BB89AD4355C5","latestVersionIndicator":"Yes","beginDate":"2011-11-18","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-11-18","modifiedBy":"ONEDATA","dateModified":"2011-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E97DE8A8-63E2-1ABC-E040-BB89AD4346F4","latestVersionIndicator":"Yes","beginDate":"2013-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"KUMMEROA","dateModified":"2019-08-16","changeDescription":". Added PV for 2402. AK 6/27/19 Added PV for 2116. AK 8/16/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Best hematologic response to line of therapy","type":"Alternate Question Text","description":"Best hematologic response to line of therapy","url":null,"context":"NHLBI"},{"name":"Best hematologic response to line of therapy","type":"Application Standard Question Text","description":"Best hematologic response to line of therapy","url":null,"context":"NHLBI"},{"name":"Compared to the disease status prior to the preparative regimen, what was the best hematologic response to HCT or cellular therapy since the date of the last report?","type":"Alternate Question Text","description":"Compared to the disease status prior to the preparative regimen, what was the best hematologic response to HCT or cellular therapy since the date of the last report?","url":null,"context":"NHLBI"},{"name":"For all recipients with primary disease multiple myeloma / plasma cell disorder (PCD) classifications excluding Amyloidosis, compared to the disease status prior to the preparative regimen, what was the best hematologic response to HCT or cellular therapy","type":"Alternate Question Text","description":"For all recipients with primary disease multiple myeloma / plasma cell disorder (PCD) classifications excluding Amyloidosis, compared to the disease status prior to the preparative regimen, what was the best hematologic response to HCT or cellular therapy since the date of the last report?","url":null,"context":"NHLBI"},{"name":"What was the best hematologic","type":"Preferred Question Text","description":"What was the best hematologic response to therapy for plasma cell myeloma?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E48EA90-B3F2-6ADB-E053-F662850AB58D","latestVersionIndicator":"Yes","beginDate":"2019-07-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-22","modifiedBy":"KUMMEROA","dateModified":"2020-02-03","changeDescription":". System generated def displayed as alt def.; System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}